Efficacy, safety and immunological response with sq house dust mite sublingual immunotherapy-tablet by body weight in children

被引：1

作者：

Sato S. ^{[1
]}

Hata H. ^{[2
]}

Kobayashi S. ^{[2
]}

Asaumi T. ^{[1
]}

Yanagida N. ^{[1
]}

Azuma R. ^{[2
]}

Ohashi-Doi K. ^{[2
]}

Ebisawa M. ^{[1
]}

机构：

[1] Department of Allergy, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital

[2] Torii Pharmaceutical Co., Ltd

来源：

Denki Kagaku | 2020年 / 69卷 / 09期

关键词：

Children; Efficacy; Immunological response; Safety; Sublingual immunotherapy;

D O I：

10.15036/arerugi.69.918

中图分类号：

学科分类号：

摘要：

Background: Sublingual immunotherapy-tablet (SLIT-tablet) treatment includes the same dose regardless of the patients' age or body weight. We investigated the efficacy, safety and immunological response of SQ house dust mite (HDM) SLIT-tablet treatment in relation to body weight in children. Methods: Total combined rhinitis score (TCRS), adverse events (AEs), adverse drug reactions (ADRs) and immunological response (IgE, IgG4) were evaluated post hoc in three subgroups (body weight ＜ 30kg, 30-44kg, ≥ 45kg) of patients from a clinical trial for Japanese children with HDM allergic rhinitis (JapicCTI-152953). Results: No apparent differences in TCRS were observed between the three subgroups. No differences in the frequency or nature of AEs were detected between the subgroups but the incidence of ADRs was decreased in the lower body weight subgroup. The most common ADRs occurred locally in the oral cavity and were categorized as mild. The levels of HDM specific IgE and IgG4 were increased compared to baseline in all subgroups. Conclusion: There were no influences of body weight for efficacy, safety, and immunological response in treatment with SQ HDM SLIT-tablet. These results indicated that SLIT dosage in children is same as adults without any concern in safety. © 2020 Japanese Society of Allergology

引用

页码：918 / 927

页数：9

共 19 条

[1] (2016)
[2] Bagnasco M, Mariani G, Passalacqua G, Motta C, Bartolomei M, Falagiani P, Et al., Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings, J Allergy Clin Immunol, 100, pp. 122-129, (1997)
[3] Bagnasco M, Passalacqua G, Villa G, Augeri C, Flamigni G, Borini E, Et al., Pharmacokinetics of an allergen and a monomeric allergoid for oromucosal immunotherapy in allergic volunteers, Clin Exp Allergy, 31, pp. 54-60, (2001)
[4] Bagnasco M, Altrinetti V, Pesce G, Caputo M, Mistrello G, Falagiani P, Et al., Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers, Int Arch Allergy Immunol, 138, pp. 197-202, (2005)
[5] Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C., Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation, J Allergy Clin Immunol, 120, pp. 707-713, (2007)
[6] Radulovic S, Jacobson MR, Durham SR, Nouri-Aria KT., Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa, J Allergy Clin Immunol, 121, pp. 1467-1472, (2008)
[7] Akdis CA, Akdis M., Advances in allergen immunotherapy: aiming for complete tolerance to allergens, Sci Transl Med, 7, pp. 280-286, (2015)
[8] Okubo K, Masuyama K, Imai T, Okamiya K, Stage BS, Seitzberg D, Et al., Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis, J Allergy Clin Immunol, 139, pp. 1840-1848, (2017)
[9] Masuyama K, Okamoto Y, Okamiya K, Azuma R, Fujinami T, Riis B, Et al., Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children, Allergy, 73, pp. 2352-2363, (2018)
[10] Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, Et al., Sub-Lingual Immunotherapy World Allergy Organization Position Paper 2009, WAO Journal, pp. 233-281, (2009)

← 1 2 →